Related Experiment Video
Updated: Jul 14, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Brain natriuretic peptide: clinical and research challenges
Rodolfo Carrillo-Jimenez1, Steven Borzak, Charles H Hennekens
1Bethesda Memorial Hospital, Boynton Beach, and Nova Southeastern College of Medicine, Ft. Lauderdale, FL, USA. dr_carrillo@yahoo.com
Journal of Cardiovascular Pharmacology and Therapeutics
|June 15, 2007
Summary
Brain natriuretic peptides help assess patients with shortness of breath and guide heart failure treatment. Serial measurements offer insights into managing heart failure, though more research is needed.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Management
Background:
- Natriuretic peptides, especially B-type (BNP), are established biomarkers for dyspnea assessment.
- Current use focuses on prognosis in heart failure and coronary syndrome.
- Limited data exists on serial natriuretic peptide measurements for treatment guidance.
Purpose of the Study:
- To review the clinical applications of natriuretic peptides.
- To discuss the limitations and practical considerations of their use.
- To highlight the potential of serial measurements in heart failure management.
Main Methods:
- Literature review of studies on natriuretic peptides.
- Analysis of clinical utility in emergency and outpatient settings.
- Evaluation of prognostic value in cardiovascular diseases.
Main Results:
- Natriuretic peptides are valuable for diagnosing dyspnea and assessing cardiac risk.
- Serial measurements may offer a pathway for optimizing heart failure therapy.
- Understanding pitfalls is crucial for accurate clinical interpretation.
Conclusions:
- Natriuretic peptides are essential tools in cardiology for patient assessment and risk stratification.
- Further investigation into serial peptide level monitoring is warranted for guiding heart failure treatment.
- Clinicians should be aware of practical aspects and limitations for effective use.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).